Oligometastatic Hormone-Sensitive Prostate Cancer. Why Radiotherapy?

被引：3

作者：

Los Arcos, Marta Barrado ^{[1
,2
]}

Lopez-Campos, Fernando ^{[3
]}

Valcarcel, Marta Lopez ^{[4
]}

Rubio, Manuel Galdeano ^{[5
]}

de Manzanos, Ignacio Visus Fernandez ^{[1
,2
]}

Duque-Santana, Victor ^{[3
]}

Aparicio, Marian Gomez ^{[6
]}

Martin, Juan Zafra ^{[7
,8
]}

Kishan, Amar U. ^{[9
,10
]}

Achard, Verane ^{[11
,12
]}

Siva, Shankar ^{[13
,14
]}

Counago, Felipe ^{[15
]}

机构：

[1] Hosp Univ Navarra, Pamplona, Navarra, Spain

[2] Inst Invest Navarra IdiSNA, Pamplona, Navarra, Spain

[3] Hosp Univ Ramon y Cajal, Madrid, Spain

[4] Hosp Univ Puerta Hierro, Madrid, Spain

[5] Hosp Terrassa Consorci Sanitari Terrassa, Terrassa, Cataluna, Spain

[6] Hosp Gen Univ Toledo, Toledo, Spain

[7] Hosp Univ Virgen Victoria, Malaga, Spain

[8] Univ Granada, Granada, Spain

[9] Univ Calif Los Angeles, Los Angeles, CA USA

[10] UCLA, Dept Radiat Oncol, Los Angeles, CA USA

[11] Hop Fribourgeois HFR Freiburger Spital HFR, Fribourg, Switzerland

[12] HUG Hop Univ Geneve, Geneva, Switzerland

[13] Peter Maallum Canc Ctr, Melbourne, Australia

[14] Univ Melbourne, Melbourne, Australia

[15] Genesis Care, La Milagrosa Hosp, San Francisco de Asis Hosp, Natl Chair Res & Clin Trials, Madrid, Spain

来源：

CLINICAL GENITOURINARY CANCER | 2023年 / 21卷 / 03期

关键词：

Metastasis-directed therapy; Metastatic prostate cancer; Radiotherapy; METASTASIS-DIRECTED THERAPY; PHASE-II TRIAL; BODY RADIOTHERAPY; MULTICENTER; RECURRENCE; SURVEILLANCE; PROGRESSION; STOMP;

D O I：

10.1016/j.clgc.2022.10.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Androgen deprivation therapy (ADT) has been considered for years the standard initial treatment for patients with metastatic prostate cancer (mPC). Recently published results support the use of taxanes, second-generation antian-drogens or radiotherapy to the primary tumor as part of the treatment in these patients, considering ADT alone as suboptimal. Metastasis-directed therapy (MDT) is used as part of the treatment for oligometastatic patients in differ-ent tumor types. In oligometastatic hormone-sensitive prostate cancer the role of MDT is being studied with promising results. In the present review we assess the available evidence for radiotherapy to the primary tumor in newly diagnosed mPC and for MDT in oligometastatic prostate cancer, as well as future directions in this clinical setting.

引用

页码：E93 / E103

页数：11

共 50 条

[1] The role of radiotherapy in oligometastatic hormone-sensitive prostate cancer
Abdel-Aty, Hoda
James, Nicholas D.
CURRENT OPINION IN UROLOGY, 2022, 32 (03) : 277 - 282
[2] Management of Oligometastatic Hormone-Sensitive Prostate Cancer
Tran, Phuoc T.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (08) : 370 - 373
[3] Developments in oligometastatic hormone-sensitive prostate cancer
Tran, Phuoc T.
Ost, Piet
WORLD JOURNAL OF UROLOGY, 2019, 37 (12) : 2545 - 2547
[4] Developments in oligometastatic hormone-sensitive prostate cancer
Ken Chow
Patrick McCoy
Ryan Stuchbery
Niall M. Corcoran
Christopher M. Hovens
World Journal of Urology, 2019, 37 : 2549 - 2555
[5] Developments in oligometastatic hormone-sensitive prostate cancer
Phuoc T. Tran
Piet Ost
World Journal of Urology, 2019, 37 : 2545 - 2547
[6] Evolving Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer
Clement, Jessica M.
Sweeney, Christopher J.
JOURNAL OF ONCOLOGY PRACTICE, 2017, 13 (01) : 9 - +
[7] Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer
Kothari, Gargi
Ost, Piet
Cheung, Patrick
Blanchard, Pierre
Tree, Alison C.
van As, Nicholas J.
Lo, Simon S.
Moghanaki, Drew
Loblaw, Andrew
Siva, Shankar
CURRENT ONCOLOGY REPORTS, 2019, 21 (05)
[8] Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer
Gargi Kothari
Piet Ost
Patrick Cheung
Pierre Blanchard
Alison C. Tree
Nicholas J. van As
Simon S. Lo
Drew Moghanaki
Andrew Loblaw
Shankar Siva
Current Oncology Reports, 2019, 21
[9] Local therapies for oligometastatic hormone-sensitive prostate cancer
Falkenbach, Fabian
Steuber, Thomas
Graefen, Markus
UROLOGIE, 2024, 63 (03): : 234 - 240
[10] SBRT for oligometastatic lymph nodes in hormone-sensitive and castration-resistant prostate cancer.
Giaj-Levra, N.
Fersino, S.
Fiorentino, A.
Tebano, U.
Aiello, D.
Mazzola, R.
Ricchetti, F.
Ruggieri, R.
Salgarello, M.
Alongi, F.
RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S832 - S832

← 1 2 3 4 5 →